comparemela.com

Latest Breaking News On - Sternir inc - Page 10 : comparemela.com

Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.

New yorkUnited statesMiltonh wernerAlex loboInhibikase therapeutics incCompany contactExchange commissionInhibikase or companyPrnewswire inhibikase therapeutics incHc wainwright coSternir incAbelson tyrosine kinasesSecurities actAbelson tyrosine kinaseAbleson tyrosineMultiple system atrophy

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson s Disease

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.

United statesMiltonh wernerAlex loboCompany complete responseInhibikase therapeutics incCompany contactDrug administrationExchange commissionInhibikase or companyPrnewswire inhibikase therapeutics incSternir incAbelson tyrosine kinasesClinical holdChief executive officerInformed consentComplete response

Inhibikase Therapeutics Announces Dosing of First Subjects in its 501 Bioequivalence Study of IkT-001Pro

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.

United statesMiltonh wernerAlex loboInhibikase therapeutics incCompany contactExchange commissionInhibikase or companySternir incInhibikase therapeuticsAbelson tyrosine kinasesChronic myelogenous leukemiaChief executiveAbelson tyrosine kinaseOrphan drug designationAbleson tyrosineMultiple system atrophy

Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs

BOSTON and ATLANTA, Dec. 7, 2022 /PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ( Inhibikase or the Company ), a clinical-stage pha.

United statesMiltonh wernerAlex loboMilton wernerInhibikase therapeutics incCompany contactDrug administrationCompany ikExchange commissionPrnewswire inhibikase therapeutics incSternir incAbelson tyrosine kinasesMultiple systemChief executiveAbelson tyrosine kinaseAbleson tyrosine

Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or the "Company"), a clinical-stage pharmaceutical company developing protein kinase.

United statesMiltonh wernerAlex loboMilton wernerInhibikase therapeutics incCompany contactDrug administrationCompany ikExchange commissionPrnewswire inhibikase therapeutics incSternir incAbelson tyrosine kinasesMultiple systemChief executiveAbelson tyrosine kinaseAbleson tyrosine

vimarsana © 2020. All Rights Reserved.